We are live on ! Find out more
Squarepoint

Squarepoint Portfolio holdings

AUM $85.1B
1-Year Est. Return 20.93%
This Fund
S&P 500
This Quarter Est. Return
+1.38%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$2.44B
AUM Growth
+$938M
Cap. Flow
+$913M
Cap. Flow %
37.33%
Top 10 Hldgs %
9.59%
Holding
2,060
New
1,079
Increased
424
Reduced
225
Closed
329

Sector Composition

Rank Sector Weight
1 Healthcare 12.2%
2 Technology 10.77%
3 Industrials 10.75%
4 Consumer Discretionary 10.73%
5 Financials 10.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NDLS icon
1701
Noodles & Co
NDLS
$90.5M
$48K ﹤0.01%
+1,450
New +$52K
NVIV
1702
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$46K ﹤0.01%
+1
New +$89.4K
HIL
1703
DELISTED
Hill International, Inc. Common Stock
HIL
$45K ﹤0.01%
+10,291
New +$40.9K
SRGA
1704
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$45K ﹤0.01%
+457
New +$41.9K
PMTS icon
1705
CPI Card Group
PMTS
$224M
$44K ﹤0.01%
+2,144
New +$49.3K
CBR
1706
DELISTED
CIBER Inc.
CBR
$44K ﹤0.01%
+69,900
New +$60.2K
VYNT
1707
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$42K ﹤0.01%
+206
New +$46.8K
QMCO icon
1708
Quantum Corp
QMCO
$437M
$41K ﹤0.01%
+305
New +$39.9K
IMBI
1709
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
$37K ﹤0.01%
+2,460
New +$46.4K
VSLR
1710
DELISTED
VIVINT SOLAR, INC.
VSLR
$36K ﹤0.01%
+13,990
New +$41.7K
LRMR icon
1711
Larimar Therapeutics
LRMR
$416M
$35K ﹤0.01%
+904
New +$36.7K
TOVX icon
1712
Theriva Biologics
TOVX
$10.2M
$35K ﹤0.01%
+5
New +$51.3K
ACGN
1713
DELISTED
Aceragen Inc
ACGN
$35K ﹤0.01%
+172
New +$41K
AUMN
1714
DELISTED
Golden Minerals Company
AUMN
$34K ﹤0.01%
+2,372
New +$40.1K
XCO
1715
DELISTED
Exco Resources
XCO
$34K ﹤0.01%
+2,570
New +$41.3K
ABUS icon
1716
Arbutus Biopharma
ABUS
$865M
$33K ﹤0.01%
+13,400
New +$39K
VANI icon
1717
Vivani Medical
VANI
$110M
$31K ﹤0.01%
+665
New +$38K
ARWR icon
1718
Arrowhead Research
ARWR
$12.1B
$30K ﹤0.01%
+19,340
New +$82.4K
DRRX
1719
DELISTED
DURECT Corp
DRRX
$30K ﹤0.01%
+2,245
New +$28.7K
TPST icon
1720
Tempest Therapeutics
TPST
$14.8M
$30K ﹤0.01%
+7
New +$87.2K
OREX
1721
DELISTED
Orexigen Therapeutics, Inc.
OREX
$27K ﹤0.01%
+15,400
New +$36.2K
ELDN icon
1722
Eledon Pharmaceuticals
ELDN
$276M
$26K ﹤0.01%
+164
New +$31.4K
GERN icon
1723
Geron
GERN
$911M
$25K ﹤0.01%
11,864
-7,536
-39% -$15.9K
NBSE
1724
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$23K ﹤0.01%
+38
New +$40.1K
CTIC
1725
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$23K ﹤0.01%
+5,690
New +$23.6K

Similar funds

Squarepoint's Q4 2016 Portfolio in Review

As of Q4 2016, Squarepoint held 2,060 positions worth $2.44B, up 62% from $1.51B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.

Squarepoint deployed $913M of net new capital in Q4 2016, opening 1,079 new positions and adding to 424 existing holdings. Its largest new stake was S&P Global: 252,484 shares worth $27.2M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 11% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Conagra Brands, an estimated $20.3M trimmed.

  • Squarepoint's largest Q4 2016 buy was S&P Global: 252,484 shares worth $27.2M.
  • Squarepoint added most to iShares China Large-Cap ETF in Q4 2016, an estimated $40.5M increase.
  • Squarepoint's biggest Q4 2016 reduction was Conagra Brands, cutting an estimated $20.3M.
  • Squarepoint fully exited State Street SPDR S&P 500 ETF Trust in Q4 2016, selling an estimated $63.7M.
  • Squarepoint's ten largest holdings make up 9.6% of its $2.44B portfolio in Q4 2016.
  • Squarepoint opened 1,079 new positions and closed 329 in Q4 2016.
  • Squarepoint's portfolio value rose 62% quarter-over-quarter to $2.44B.

Based on Squarepoint's 13F filing for Q4 2016, filed 14 Feb 2017.